Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Dorr

Showing results (21-30 of 184) with videos related to

Pageof 19
Sort By:
Peptides|January 18, 2006
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercializationMac E Hadley, Robert T Dorr
Anticancer Research|September 1, 1994
Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cellsN S Paranka, R T Dorr
Cancer Chemotherapy and Pharmacology|January 1, 1991
Modulation of mitomycin C-induced multidrug resistance in vitroR T Dorr, J D Liddil
Cancer Treatment Reports|November 1, 1981
Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compoundsR T Dorr, D S Alberts
Journal of Cancer Research and Clinical Oncology|January 1, 1989
H2-antagonists and carmustineR T Dorr, M J Soble
Anticancer Research|January 1, 1988
Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in miceM J Soble, R T Dorr
Cancer|August 15, 1992
Topical absorption and inactivation of cytotoxic anticancer agents in vitroR T Dorr, D S Alberts
Investigational New Drugs|January 1, 1983
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluentsR T Dorr, D S Alberts
Cancer Research|June 1, 1981
Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compoundsR T Dorr, D S Alberts
Cancer Treatment Reviews|January 1, 1995
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal functionP E Kintzel, R T Dorr
Pageof 19

Showing results (21-30 of 184) with videos related to

Sort By:
Pageof 19
Peptides|January 18, 2006
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercializationMac E Hadley, Robert T Dorr
Anticancer Research|September 1, 1994
Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cellsN S Paranka, R T Dorr
Cancer Chemotherapy and Pharmacology|January 1, 1991
Modulation of mitomycin C-induced multidrug resistance in vitroR T Dorr, J D Liddil
Cancer Treatment Reports|November 1, 1981
Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compoundsR T Dorr, D S Alberts
Journal of Cancer Research and Clinical Oncology|January 1, 1989
H2-antagonists and carmustineR T Dorr, M J Soble
Anticancer Research|January 1, 1988
Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in miceM J Soble, R T Dorr
Cancer|August 15, 1992
Topical absorption and inactivation of cytotoxic anticancer agents in vitroR T Dorr, D S Alberts
Investigational New Drugs|January 1, 1983
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluentsR T Dorr, D S Alberts
Cancer Research|June 1, 1981
Modulation of experimental doxorubicin skin toxicity by beta-adrenergic compoundsR T Dorr, D S Alberts
Cancer Treatment Reviews|January 1, 1995
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal functionP E Kintzel, R T Dorr
Pageof 19